REGENERON PHARMACEUTICALS, INC. - DEF 14A

Company

REGENERON PHARMACEUTICALS, INC.

Filed

April 25, 2024

Period of Report

June 14, 2024

Accession Number

0001308179-24-000577

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →